Cyclerion Therapeutics Inc.
13F holders, Q3 2024 (September 30)15holders −2
0new positions
3sold out
$2.59avg. 13F price*
At the end of Q3 2024, 15 institutions reported holding Cyclerion Therapeutics Inc. in their 13F filings, down 2 from Q2 2024. 0 opened new positions and 3 sold out. The largest holders were Slate Path Capital LP ($927K), MFN Partners Management, LP ($437K) and Tyndall Capital Partners L P ($427K).
- Company
- Cyclerion Therapeutics Inc.
- CUSIP
- 23255M204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $272K |
All 13F filers, Q2 2024 → Q3 2024: 7 shares bought and 124,861 shares sold, net −124,854 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Slate Path Capital LP | 0.02% | No change | 357,880 | $927K |
| MFN Partners Management, LP | 0.01% | No change | 169,460 | $437K |
| Tyndall Capital Partners L P | 100.00% | No change | 164,777 | $427K |
| FMR LLC | 0.00% | Reduce -2.3% | 157,636 | $407K |
| Siren, L.L.C. | 0.02% | — | 116,155 | $301K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.2% | 33,908 | $88K |
| Vanguard Group Inc. | 0.00% | No change | 23,490 | $61K |
| BlackRock, Inc. | 0.00% | — | 16,797 | $44K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -26.4% | 1,078 | $3K |
| Morgan Stanley | 0.00% | No change | 649 | $2K |
| Group One Trading LLC | 0.00% | No change | 540 | $1K |
| UBS Group AG | 0.00% | Reduce -94.6% | 145 | $376 |
| Activest Wealth Management | 0.00% | No change | 100 | $259 |
| Bank of America Corp. | 0.00% | Add +43.8% | 23 | $59 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is CYCLERION THERAPEUTICS INC's weight in each manager's 13F, not the share of Cyclerion Therapeutics Inc. the manager owns.